Treatment of B-cell non-Hodgkin's lymphoma with anti-CD20 monoclonal antibodies.

• Tobinai Kensei

  Hematology Division, National Cancer Center Hospital

Bibliographic Information

Other Title

• 逐に開始されたモノクローナル抗体による治療　　抗ＣＤ２０抗体によるＢ細胞リンパ腫の治療
• Treatment of B-cell non-Hodgkin's lymphoma with anti-CD20 monoclonal antibodies
• 抗CD20抗体によるB細胞リンパ腫の治療

Abstract

The CD 20 antigen is expressed consistently on nearly all human B-cells and B-lymphoma cells. Rituximab is a chimeric IgG 1 kappa monoclonal antibody (mAb) with mouse variable and human constant regions that recognizes the CD 20 antigen. In vitro experiments have revealed that rituximab lyses human B-cells through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. The toxicities of rituximab are mainly non-hematological grade 1 or 2 episodes. Hematological toxicities are not severe. In the phase I/II study in the USA, an overall response rate (ORR) of 50% was obtained in relapsed low-grade B-cell lymphoma. The median time to progression (TTP) of the responders was 10.2 months. The good response rate and fairly long TTP were reproduced in a subsequent pivotal trial, which enrolled 166 patients with low-grade or follicular B-cell lymphoma. In the phase I study in Japan, 12 patients with relapsed CD 20⁺B-cell lymphoma were enrolled : 4 at 250 mg/m² and 8 at 375 mg/m², once a week for 4 weeks. Of the 11 eligible pts, 2 showed CR and 5 showed PR. 90 relapsed pts were enrolled in the subsequent phase II study and treated with rituximab at 375 mg/m² × 4 weekly infusions. The ORR in indolent B-dell lymphoma and MCL were 61% (37/61) and 46% (6/13), respectively. Several trials of rituximab in combination with chemotherapy have revealed promising results not only for indolent B-cell lymphoma but also for aggressive B-cell lymphoma. Particularly, rituximab plus CHOP therapy might become a new standard regimen for untreated aggressive B-cell lymphoma.

Journal

• Drug Delivery System

  Drug Delivery System 17 (1), 35-41, 2002

  THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Keywords

• monoclonal antibody
• B-cell lymphoma
• CD20
• rituximab
• radioimmunotherapy

Details

• CRID: 1390001204640470016
• NII Article ID: 10008132011
• NII Book ID: AN10084591
• DOI: 10.2745/dds.17.35
• ISSN: 18812732
• ISSN: 09135006
• Web Site: https://search.jamas.or.jp/link/ui/2002187709
• Text Lang: ja
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed